| Features: |
| Treatment of disease with radiation, especially by selective irradiation with x-rays or other ionizing radiation and by ingestion of radioisotopes. Radiosensitizer Atorvaqone, (mitochondria inhibitor) decrease O2 consumption making more O2 available as a radiosensitizer. |
| Source: |
| Type: |
| 12‐lipoxygenase (commonly abbreviated as 12-LOX) 12-LOX (12-lipoxygenase) is an enzyme that plays a role in the metabolism of polyunsaturated fatty acids—in particular, converting arachidonic acid into bioactive lipid mediators such as 12-hydroxyeicosatetraenoic acid (12-HETE). -12-LOX is implicated in several mechanisms that can promote cancer, including supporting inflammation, cell survival, angiogenesis, and metastasis. High 12-LOX expression in several cancer types is generally correlated with more aggressive disease and poorer clinical outcomes. However, the prognostic significance may vary between cancers and patient populations. Ongoing research is aiming to clarify: – Whether 12-LOX can be reliably used as a prognostic biomarker – And whether targeting 12-LOX might serve as a therapeutic strategy in cancer management. – Increased Levels of 12-LOX in ESCC Patients with Poor Prognosis |
| 2481- | Ba, | Rad, | Radiotherapy Increases 12-LOX and CCL5 Levels in Esophageal Cancer Cells and Promotes Cancer Metastasis via THP-1-Derived Macrophages |
| - | in-vitro, | ESCC, | Eca109 | - | in-vitro, | ESCC, | KYSE150 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:201 Target#:1126 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid